{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22"}],"title":"Poor Response"},{"measurements":[{"groupId":"OG000","value":"18"}],"title":"Good Response"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"The association of interested variables with response was checked with the Wilcoxon rank-sum test. The response is based on the Huvos grade of histologic response for DCE-MRI comparisons and is defined as good for ≥90% necrosis and poor for less than 90%.","groups":[{"description":"All 42 evaluable participants in this study had osteosarcoma. This analysis includes 29 Stratum A participants who had primary tumors potentially resectable by aggressive surgery, such as limb-salvage surgery or amputation, and no evidence of metastasis, and 11 Stratum C participants who had metastatic tumors.","id":"OG000","title":"All Participants"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Two Stratum A participants with no histologic response were excluded.","reportingStatus":"POSTED","timeFrame":"at week 10 after start of therapy","title":"Histologic Response by Number of Participants","type":"SECONDARY","unitOfMeasure":"Participants"}